Recurrencia y mortalidad a largo plazo de los pacientes con síncope no cardiogénico / Long-term recurrences and mortality in patients with noncardiac syncope

Introducción y objetivos: La evolución a largo plazo de los pacientes que padecen síncope, una vez descartada su etiología cardiaca, no se ha descrito en profundidad. Se describe la evolución a largo plazo de esta población. Métodos: Durante 147 meses, se estudió a todos los pacientes remitidos a nuestra unidad de síncope tras haberse descartado una causa cardiaca. Resultados: Se incluyó a 589 pacientes consecutivos, 313 de ellos mujeres (53,1%), con una mediana de 52 [34-66] años. A 405 (68,8%) se les diagnosticó síncope vasovagal (SVV); a 65 (11%), síncope por hipotensión ortostática (SHO), y a 119 (20,2%), síncope de etiología desconocida (SED). Durante una mediana de 52 [28-89] meses de seguimiento, 220 (37,4%) tuvieron recurrencias (el 21,7%, 2 o más recurrencias) y se produjeron 39 muertes (6,6%). La recurrencia del síncope se produjo en el 41% de los pacientes con SVV, el 35,4% del grupo con SHO y el 25,2% del de SED (p=0,006). La recurrencia se correlacionó en el análisis multivariado con la edad (p=0,002), el sexo femenino (p<0,0001) y el número de episodios previos (< 5 frente a ≥ 5; p <0,0001). Fallecieron 15 pacientes (3,5%) con SVV, 11 (16,9%) con SHO y 13 (10,9%) con SED (p=0,001), El análisis multivariado asoció edad (p=0,0001), diabetes (p=0,007) y diagnóstico de SHO (p=0,026) y SED (p=0,020) con la muerte. Conclusiones: En los pacientes con síncope de origen no cardiaco, a los 52 meses de seguimiento, la tasa de recurrencias es del 37,4% y la de mortalidad, del 6,6%. Hay más recurrencias en los pacientes con perfil neuromediado y más mortalidad en los pacientes con perfil no neuromediado (AU)

Introduction and objectives: There are no in-depth studies of the long-term outcome of patients with syncope after exclusion of cardiac etiology. We therefore analyzed the long-term outcome of this population. Methods: For 147 months, we included all patients with syncope referred to our syncope unit after exclusion of a cardiac cause. Results: We included 589 consecutive patients. There were 313 (53.1%) women, and the median age was 52 [34-66] years. Of these, 405 (68.8%) were diagnosed with vasovagal syncope (VVS), 65 (11%) with orthostatic hypotension syncope (OHS), and 119 (20.2%) with syncope of unknown etiology (SUE). During a median follow-up of 52 [28-89] months, 220 (37.4%) had recurrences (21.7% ≥ 2 recurrences), and 39 died (6.6%). Syncope recurred in 41% of patients with VVS, 35.4% with OHS, and 25.2% with SUE (P=.006). In the Cox multivariate analysis, recurrence was correlated with age (P=.002), female sex (P <.0001), and the number of previous episodes (< 5 vs ≥ 5; P <.0001). Death occurred in 15 (3.5%) patients with VVS, 11 (16.9%) with OHS, and 13 (10.9%) with SUE (P=.001). In the multivariate analysis, death was associated with age (P=.0001), diabetes (P=.007), and diagnosis of OHS (P=.026) and SUE (P=.020). Conclusions: In patients with noncardiac syncope, the recurrence rate after 52 months of follow-up was 37.4% and mortality was 6.6% per year. Recurrence was higher in patients with a neuromedial profile and mortality was higher in patients with a nonneuromedial profile (AU)

Calidad de vida, adherencia y satisfacción en pacientes con fibrilación auricular tratados con dabigatrán o antagonistas de la vitamina K / Quality of life, adherence and satisfaction of patients with auricular fibrillation treated with dabigatran or vitamin K antagonists

Objetivo: Analizar la calidad de vida, la adherencia y la percepción del grado de satisfacción del tratamiento con dabigatrán frente a antagonistas de vitamina K (AVK) en pacientes con fibrilación auricular no valvular (FANV) atendidos en consultas de cardiología en España. Métodos: Estudio observacional, comparativo, prospectivo y multicéntrico en pacientes con FANV atendidos en Cardiología, que iniciaron tratamiento con dabigatrán o AVK en el mes previo a la visita basal. El seguimiento fue de 6 meses. Se analizaron la calidad de vida mediante el cuestionario validado AF-QoL 18 (0: mínimo; 100: máximo), la adherencia mediante el test de Morisky-Green y la percepción del cardiólogo mediante un cuestionario específico (0: completamente insatisfecho; 10: totalmente satisfecho). Resultados: Se analizó a 1.015 pacientes (73,3+/- 9,4 años; 57% varones; CHA2DS2VASc: 3,4+/- 1,5; HAS-BLED: 1,5+/- 1,0), tratados con dabigatrán (74,7%) o con AVK (25,3%). Las puntuaciones totales de calidad de vida se mantuvieron constantes durante el seguimiento (47,9+/- 23,5 basalmente vs. 48,6+/- 24,4 a los 6 meses; p=NS), pero superiores a los 6 meses en el grupo de dabigatrán (50,6+/- 24,7 vs. 42,8+/- 22,5; p<0,001). La adherencia al tratamiento fue elevada durante el estudio, pero superior con dabigatrán a los 6 meses (89,2% vs. 81,1%; p=0,001). Existió una mejor percepción del cardiólogo sobre la satisfacción de los pacientes tratados con dabigatrán a los 6 meses (9,0+/-1,2 vs. 6,6+/-2,2; p<0,001). Conclusiones: En pacientes con FANV y alto riesgo tromboembólico atendidos en consultas de Cardiología, tanto la adherencia como la satisfacción y la calidad de vida fueron superiores en los pacientes tratados con dabigatrán que con AVK

Objective: To analyse the quality of life, adherence and satisfaction of patients with nonvalvular auricular fibrillation (NVAF) treated with dabigatran versus vitamin K antagonists (VKA) in cardiology consultations in Spain. Methods: We conducted an observational, comparative, prospective and multicentre study of patients with NVAF treated in cardiology departments, who started treatment with dabigatran or VKA in the month prior to the baseline visit. The follow-up lasted 6 months. We analysed quality of life (using the validated AF-QoL 18 questionnaire [0, minimum; 100, maximum]), adherence (using the Morisky-Green test) and the cardiologist's perception (using a specific questionnaire [0, completely dissatisfied; 10, completely satisfied]). Results: We analysed 1015 patients (mean age, 73.3+/-9.4 years; 57% men; CHA2DS2VASc, 3.4+/-1.5; HAS-BLED, 1.5+/-1.0) who were treated with dabigatran (74.7%) or with VKA (25.3%). The total quality-of-life scores remained constant throughout the follow-up (47.9+/-23.5 and 48.6+/-24.4 at baseline and at 6 months, respectively; P=NS) but were higher at 6 months for the dabigatran group (50.6+/-24.7 vs. 42.8+/-22.5; P<.001). Treatment adherence was high during the study but greater with dabigatran at 6 months (89.2% vs. 81.1%; P=.001). There was a better perception of the cardiologist regarding the satisfaction of the patients treated with dabigatran at 6 months (9.0+/-1.2 vs. 6.6+/-2.2; P<.001). Conclusions: For patients with NVAF and high thromboembolic risk treated in cardiology consultations, the adherence, satisfaction and quality of life were higher for the patients treated with dabigatran than for those treated with VKA

Quality of life, adherence and satisfaction of patients with auricular fibrillation treated with dabigatran or vitamin K antagonists. / Calidad de vida, adherencia y satisfacción en pacientes con fibrilación auricular tratados con dabigatrán o antagonistas de la vitamina K.

OBJECTIVE: To analyse the quality of life, adherence and satisfaction of patients with nonvalvular auricular fibrillation (NVAF) treated with dabigatran versus vitamin K antagonists (VKA) in cardiology consultations in Spain. METHODS: We conducted an observational, comparative, prospective and multicentre study of patients with NVAF treated in cardiology departments, who started treatment with dabigatran or VKA in the month prior to the baseline visit. The follow-up lasted 6 months. We analysed quality of life (using the validated AF-QoL 18 questionnaire [0, minimum; 100, maximum]), adherence (using the Morisky-Green test) and the cardiologist's perception (using a specific questionnaire [0, completely dissatisfied; 10, completely satisfied]). RESULTS: We analysed 1015 patients (mean age, 73.3±9.4 years; 57% men; CHA2DS2VASc, 3.4±1.5; HAS-BLED, 1.5±1.0) who were treated with dabigatran (74.7%) or with VKA (25.3%). The total quality-of-life scores remained constant throughout the follow-up (47.9±23.5 and 48.6±24.4 at baseline and at 6 months, respectively; P=NS) but were higher at 6 months for the dabigatran group (50.6±24.7 vs. 42.8±22.5; P<.001). Treatment adherence was high during the study but greater with dabigatran at 6 months (89.2% vs. 81.1%; P=.001). There was a better perception of the cardiologist regarding the satisfaction of the patients treated with dabigatran at 6 months (9.0±1.2 vs. 6.6±2.2; P<.001). CONCLUSIONS: For patients with NVAF and high thromboembolic risk treated in cardiology consultations, the adherence, satisfaction and quality of life were higher for the patients treated with dabigatran than for those treated with VKA.

[Evaluation of high risk syncope referred from emergency department]. / Evaluación del síncope de alto riesgo remitido desde el Servicio de Urgencias.

INTRODUCTION: High-risk syncope (over aged 60, abnormal electrocardiogram, syncope without prodromes and/or background of cardiovascular disease) is associated with high mortality. More detailed attention to that which may often be considered as an emergency should be given. We have evaluated the activity of a specialized service in the care of syncope in an internal medicine service. MATERIAL AND METHODS: We have collected a series of patients diagnosed in the emergency service of "syncope." The patients were referred to the specialized unit in the care of syncope and evaluated in less than 72h. We analyzed the tests made to establish a pathophysiological diagnosis of syncope. RESULTS: A total of 107 consecutive patients were studied, 82 of whom met the criteria for being at risk of syncope. All underwent an echocardiography and outpatient Holter. A total of 23 studies were performed with tilt test, 4 electrophysiological studies were performed and 2 were implanted with an insertable Holter. A specific diagnosis could be established in 73 patients. Three patients were diagnosed with a neurological disease. The most frequent cause of the syncope was neuromediated (41 patients). After a mean follow-up of over 2 years, total mortality (9 patients) was not related with the syncope. CONCLUSIONS: A specialized service in the care of high-risk syncope increases the percentage of patients with a definitive diagnosis.

Evaluación del síncope de alto riesgo remitido desde el Servicio de Urgencias / Evaluation of high risk syncope referred from emergency department

Introducción El síncope de alto riesgo (más de 65 años, electrocardiograma anormal, síncope sin pródromos y/o antecedentes de patología cardiovascular) se asocia a una elevada mortalidad. Parece aconsejable una atención más detallada de la que puede ofrecerse en Urgencias. Hemos evaluado la actividad de una consulta monográfica de síncope en un Servicio de Cardiología. Material y métodos Hemos recogido una serie de enfermos diagnosticados en Urgencias de «sincope». Los enfermos fueron remitidos a la consulta monográfica de síncope y evaluados en menos de 72h. Hemos analizado las pruebas realizadas para establecer un diagnóstico fisiopatológico del síncope. Resultados Estudiamos 107 pacientes consecutivos, de los que 82 cumplían criterios de síncope de riesgo. A todos se les realizó una ecocardiografía y un Holter ambulatorio. Se realizaron 23 estudios con mesa basculante, 4 estudios electrofisiológicos, y se implantaron 2 Holter insertables. En 73 pacientes pudimos establecer un diagnóstico concreto. Tres pacientes fueron diagnosticados de una enfermedad neurológica. La causa más frecuente del síncope fue la neuromediada (41 pacientes). Tras un seguimiento medio superior a 2 años, la mortalidad total (9 pacientes) no se relacionó con el síncope. Conclusiones Una consulta especializada en síncope de alto riesgo aumenta el porcentaje de pacientes con diagnóstico definitivo(AU)

Introduction High-risk syncope (over aged 60, abnormal electrocardiogram, syncope without prodromes and/or background of cardiovascular disease) is associated with high mortality. More detailed attention to that which may often be considered as an emergency should be given. We have evaluated the activity of a specialized service in the care of syncope in an internal medicine service. Material and methods We have collected a series of patients diagnosed in the emergency service of “syncope.” The patients were referred to the specialized unit in the care of syncope and evaluated in less than 72h. We analyzed the tests made to establish a pathophysiological diagnosis of syncope. Results A total of 107 consecutive patients were studied, 82 of whom met the criteria for being at risk of syncope. All underwent an echocardiography and outpatient Holter. A total of 23 studies were performed with tilt test, 4 electrophysiological studies were performed and 2 were implanted with an insertable Holter. A specific diagnosis could be established in 73 patients. Three patients were diagnosed with a neurological disease. The most frequent cause of the syncope was neuromediated (41 patients). After a mean follow-up of over 2 years, total mortality (9 patients) was not related with the syncope. Conclusions A specialized service in the care of high-risk syncope increases the percentage of patients with a definitive diagnosis(AU)

Disfunción diastólica con fracción de eyección conservada en una paciente con enfermedad de Paget poliostótica / Diastolic dysfunction with preserved ejection fraction in a patient with Paget´s disease of bone

No disponible

Long-term outcome of patients with asystole induced by head-up tilt test.

AIMS: To analyse the long-term outcome of the largest reported cohort of patients presenting asystole during head-up tilt test. METHODS AND RESULTS: Since 1990, 1322 patients with syncope of unknown origin have undergone tilt-table testing. Of those, 330 patients (24 X 9%) presented an abnormal response (syncope or pre-syncope). Furthermore, 58 of those patients (17 X 5%) suffered a period of asystole (> or = 3000 ms) during the test. Asystole (median (interquartile range)) lasted 10 (4, 19 X 2) s (range 3-90). Two different protocols (angles) of tilting (Westminster (60 degrees) n=1124; isoproterenol (80 degrees) n=198)) influenced the time to the syncopal episode (13 (6 X 5, 20 X 5) vs 2 (1, 6 X 5) min, P=0,0005) but not the duration of the asystole. During this period, therapy for asystole featured three different stages: first patients were treated with pacemakers; later drug therapy (metoprolol and/or etilefrine) was recommended; lastly (from 1995), no specific treatment was given. In a cohort age- and gender-matched study, those patients without were compared to those with asystole in a 2:1 basis. During 40 X 7 months of follow-up (17 X 7, 66 X 8), 12 patients (20 X 6%) with asystole had syncopal recurrences. Furthermore, 34 patients (28 X 8%) without asystole presented syncopal episodes during a follow-up of 51 X 6 months (29 X 3, 73 X 1) (P=ns). The Kaplan-Meier analysis in patients with and without asystole showed a mean time free of recurrence of 92 X 6 +/- 6 months vs 82 X 6 +/- 4 X 7 months (P=ns). The previous number of syncopes had a significant relationship with recurrences (P=0 X 002), but not therapy. There were no cardiac related deaths. CONCLUSIONS: (1) Asystole during head-up tilt test does not imply a malignant outcome and syncope recurrence is low; (2) pacemaker or drug therapy do not significantly influence outcome which correlates to the previous number of syncopal episodes but not to gender, age, asystole occurrence, asystole duration and timing to asystole during head-up tilt test; (3) tilting protocol (angle) might influence time to and incidence of asystole during head-up tilt test.

Age and gender differences in basal and isoprenaline protocols for head-up tilt table testing.

AIMS: Syncope is a common occurrence, the prevalence of which increases with age, and among the multiple causes of syncope, neurally mediated syncope is thought to be a frequent cause in the young and in the elderly. Head-up tilt table testing (HUT) has become the diagnostic test of choice for neurally mediated syncope, the response to which varies clearly with age. The purpose of this study is to report the differences among patients suffering syncope referred for HUT, and the influence of age and gender on HUT results (percentage of positive responses and response patterns) in two study protocols (basal and isoprenaline). METHODS AND RESULTS: One thousand, two hundred and nineteen patients with syncope were referred to the authors' Cardiology Department for HUT from September 1990 to April 2000; 1061 undergoing basal HUT (Group A) and 158 undergoing isoprenaline tilt table testing (Group B). Complications were noted in neither protocol. Females were more frequent among young people, and males in the elderly (P<0.05). Head-up tilt table testing was abnormal in 259 (24.4%) patients in Group A and in 85 (53.7%) patients in Group B (P<0.05), and no gender differences were observed. The positive rate of tests in men and women significantly declined with age in Group A (P<0.05), but not in Group B (P=ns). There were no differences in the patterns of haemodynamic collapse in both groups. CONCLUSIONS: In the study of syncope, basal HUT has a high positive rate in young people; a decrease in positive rate with age suggests, however, the need for using another protocol with a similar diagnostic accuracy in the elderly.

[Advanced auriculoventricular block of atypical presentation after acute myocardial infarct in sleep apnea syndrome]. / Bloqueo auriculoventricular avanzado de presentación atípica tras infarto agudo de miocardio en el síndrome de apnea del sueño.

We report a case of an adult male in whom, one week after an anterior acute myocardial infarction, we documented nocturnal episodes of type II second degree atrio-ventricular heart block, including advanced heart block episodes (4:1). An electrophysiologic study did not show atrio-ventricular conduction abnormalities, so we suspected a possible sleep apnea syndrome, which was confirmed with a polysomnographic study. It was observed that advanced heart block episodes were preceded by significant decreases in arterial oxygen saturation. These episodes disappeared with continuous positive air pressure ventilation.